What is Regeneron Pharmaceuticals's finished goods?

Regeneron Pharmaceuticals (REGN) reported finished goods of $160.5M in Q1 2026.

How has Regeneron Pharmaceuticals's finished goods changed year-over-year?

Regeneron Pharmaceuticals's finished goods increased by 45.9% year-over-year, from $110M to $160.5M.

What is the long-term trend for Regeneron Pharmaceuticals's finished goods?

Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's finished goods has grown at a 9.3% compound annual growth rate (CAGR), from $121.7M to $190.2M.

Regeneron Pharmaceuticals REGN Finished goods

Finished goods at other companies

AmgenAMGN

——

Other financials

Income statement

See full

Revenue$3.6B+19.0%

Operating income$642.9M+8.7%

Net income$727.2M-10.1%

EPS (diluted)$6.75-7.2%

Balance sheet

See full

Cash & equivalents$3.0B-4.0%

Total debt$2.7B+0.1%

Total equity$31.4B+6.9%

Total assets$40.9B+8.9%

Cash flow

See full

Operating cash flow$1.1B+3.2%

CapEx$230.6M+0.6%

Free cash flow$848.3M+4.0%

Valuation

See full

Market cap$65.37B+21.9%

Enterprise value$65.11B+20.0%

P/E14.8×+2.8×

P/S4.4×+0.6×

Profitability

See full

Gross margin93.9%—

Operating margin24.3%-2.9pp

Net margin29.6%-2.3pp

FCF margin27.6%+5.5pp

Returns & leverage

See full

Return on equity14.5%-1.4pp

Debt / equity0.1×0.0×

Current ratio3.6×-1.4×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regeneron Pharmaceuticals's finished goods?: Regeneron Pharmaceuticals (REGN) reported finished goods of $160.5M in Q1 2026.
How has Regeneron Pharmaceuticals's finished goods changed year-over-year?: Regeneron Pharmaceuticals's finished goods increased by 45.9% year-over-year, from $110M to $160.5M.
What is the long-term trend for Regeneron Pharmaceuticals's finished goods?: Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's finished goods has grown at a 9.3% compound annual growth rate (CAGR), from $121.7M to $190.2M.